CARLSBAD, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announces the following webcast:
http://www.isispharm.com
If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at http://www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world’s first antisense drug and has 18 drugs in development. Isis’ drug development programs are focused on treating cardiovascular and metabolic diseases. Isis’ partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis’ wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide, and Isis is a joint owner of Regulus Therapeutics, LLC, a company focused on the discovery, development and commercialization of microRNA therapeutics. Additional information about Isis is available at http://www.isispharm.com.
CONTACT: Kristina Lemonidis, Associate Director, Investor Relations,
+1-760-603-2331, or Amy Blackley, Ph.D., Manager, Corporate Communications,
+1-760-603-2772, both of Isis Pharmaceuticals, Inc.
Web site: http://www.isispharm.com//
